• Maria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, Enrico Orciuolo, Francesco Ghio, Sara Ciofini, Veronica Candi, Giulia Fontanelli, Irene Attucci, Giuseppe Formica, Monica Bocchia, Sara Galimberti, Mario Petrini, and Gabriele Buda.
• Hematology Unit, Department of Clinical And Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
• Medicina (Kaunas). 2021 Aug 28; 57 (9).

AbstractBackground and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy.

17 keywords...

hide…